Thomas M. Fletcher

Development and Validation of a High-Throughput Screen for Inhibitors of SARS CoV and Its Application in Screening of a 100,000-Compound Library

E Lucile White, Subramaniam Ananthan, C. Jonsson, 2007, SLAS Discovery.

in Screening of a 100,000-Compound Library Development and Validation of a High-Throughput Screen for Inhibitors of SARS CoV and Its Application

B. Jonsson, E. White, W. Severson, 2013 .

A Novel Inhibitor of Mycobacterium tuberculosis Pantothenate Synthetase

David Eisenberg, Lynn Rasmussen, E. Lucile White, 2007, Journal of biomolecular screening.

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

W. Greenhalf, T. Jaki, S. Khoo, 2021, The Journal of antimicrobial chemotherapy.

Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial

W. Greenhalf, S. Khoo, D. Lalloo, 2022, Nature Communications.

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

Jonathon P. Baker, F. Hayden, W. Greenhalf, 2022, The Lancet Infectious Diseases.

Development and Application of a High-Throughput Screening Assay for HIV-1 Integrase Enzyme Activities

C. Jonsson, S. John, Thomas M. Fletcher, 2005, Journal of biomolecular screening.